

Track 1 Clinical diagnosis, imaging and biomarkers of MS

Track 2 Therapeutics in MS

Track 3 Pathology

Track 4 MS differential diagnosis

Each track includes 6 sessions. Two sessions will take place during the ECTRIMS Congress (13-15 October 2021), followed by 4 sessions that take place in the weeks after the congress. Tickets can be bought for an entire track or just specific sessions.

Track 1 Clinical diagnosis, imaging and biomarkers of MS

Wednesday, 13 October 2021, 13.15 – 14.15

Educational Session 4: Diagnosis of MS

Chair: Georgina Arrambide (Barcelona, Spain)

Chair: Johannes Lorscheider (Basel, Switzerland)

13:15

Introduction by chairs

13:20

The MS diagnostic criteria in clinical practice

Speaker: Georgina Arrambide (Barcelona, Spain)

13:35

When does progression start?

Speaker: Johannes Lorscheider (Basel, Switzerland)

13:50

Red flags and extreme presentation of MS

Speaker: Pierre Labauge (Montpellier, France)

14:05

Live Discussion

Friday, 15 October 2021, 12:00 – 13:00

Educational Session 7: Early stages of MS

Chair: Russell Dale (Sydney, Australia)

Chair: Christine Lebrun-Frenay (Nice, France)

12:00

Introduction by chairs

12:05

When does the disease start? MS Prodrome

Speaker: Ruth Ann Marrie (Winnipeg, Canada)

12:20

The radiologically isolated syndrome (RIS), is it already MS?

Speaker: Christine Lebrun-Frenay (Nice, France)

12:35

How could paediatric MS shed light on early MS?

Speaker: Russell Dale (Sydney, Australia)

12:50

Live Discussion

Friday, 29 October 2021, 15:00 – 16:00

Educational Session 9: A closer and quantitative look on in vivo MS pathology (MAGNIMS)

Chair: Maria Assunta Rocca (Milan, Italy)

Chair: Cristina Granziera (Basel, Switzerland)

15:00

Introduction by chairs

15:05

Imaging myelin damage

Speaker: Maria Assunta Rocca (Milan, Italy)

15:20

Imaging axonal damage

Speaker: Cristina Granziera (Basel, Switzerland)

16:35

Imaging MS lesion heterogeneity with susceptibility MRI

Speaker: Daniel S. Reich (Bethesda, United States)

15:50

Live Discussion

Friday, 29 October 2021, 16:15 – 17:15

Educational Session 11: ECTRIMS/EANM teaching course on molecular imaging

Chair: Bruno Stankoff (Paris, France)

Chair: Laura Airas (Turku, Finland)

16:15

Introduction by chairs

16:20

Molecular imaging of the neuro-inflammatory component in MS

Speaker: Laura Airas (Turku, Finland)

16:35

Metabolic imaging in MS

Speaker: Matilde Inglese (Genoa, Italy)

16:50

Imaging myelin content change: PET or MRI?

Speaker: Bruno Stankoff (Paris, France)

17:05

Live Discussion

Friday, 26 November 2021, 15:00 – 16:00

Educational Session 17: Biomarkers in MS

Chair: Jens Kuhle (Basel, Switzerland)

Chair: Charlotte Teunissen (Amsterdam, Netherlands)

15:00

Introduction by chairs

15:05

NfL for prognostic and therapeutic follow up of patients with MS

Speaker: Jens Kuhle (Basel, Switzerland)

15:20

Other blood biomarkers in MS

Speaker: Fredrik Piehl (Stockholm, Sweden)

15:35

CSF biomarkers in MS

Speaker: Charlotte Teunissen (Amsterdam, Netherlands)

15:50

Live Discussion

Friday, 26 November 2021, 16:15 – 17:15

Educational Session 19: Visual outcomes in MS and NMOSD

Chair: Letizia Leocani (Milan, Italy)

Chair: Angela Vidal-Jordana (Barcelona, Spain)

16:15

Introduction by chairs

16:20

Visual evoked potentials in MS and NMOSD

Speaker: Letizia Leocani (Milan, Italy)

16:35

OCT in MS and NMOSD

Speaker: Angela Vidal-Jordana (Barcelona, Spain)

16:50

Functional and structural MR imaging of the visual system in MS and NMOSD

Speaker: Friedemann Paul (Berlin, Germany)

17:05

Live Discussion

Track 2 Therapeutics in MS

Wednesday, 13 October 2021, 12:00 – 13:00

Educational Session 2: Treatment of relapsing-remitting MS

Chair: Frauke Zipp (Mainz, Germany)

Chair: Maria Trojano (Bari, Italy)

12:00

Introduction by chairs

12:05

Should every relapsing MS patient be treated?

Speaker: Jaume Sastre-Garriga (Barcelona, Spain)

12:20

Switching treatments: when and how?

Speaker: Frauke Zipp (Mainz, Germany)

12:35

Is there a place for induction treatment?

Speaker: Maria Trojano (Bari, Italy)

12:50

Live Discussion

Wednesday, 13 October 2021, 13:15 – 14:15

Educational Session 3: Treatment of progressive MS

Chair: Xavier Montalban (Barcelona, Spain)

Chair: Jeremy Chataway (London, United Kingdom)

13:15

Introduction by chairs

13:20

Which progressive patient should be treated?

Speaker: Xavier Montalban (Barcelona, Spain)

13:35

How to monitor treatment responses in progressive patients?

Speaker: Daniel Ontaneda (Cleveland, United States)

13:50

Future treatment options for progressive MS

Speaker: Jeremy Chataway (London, United Kingdom)

14:05

Live Discussion

Friday, 29 October 2021, 15:00 - 16:00

Educational Session 10: Specific aspects of MS treatment

Chair: Sandra Vukusic (Lyon, France)

Chair: Clemens Warnke (Cologne, Germany)

15:00

Introduction by chairs

15:05

DMTs in women planning or during pregnancy

Speaker: Sandra Vukusic (Lyon, France)

15:20

DMTs in elderly patients

Speaker: Clemens Warnke (Cologne, Germany)

15:35

Stopping DMTs

Speaker: Gabriel Bsteh (Vienna, Austria)

15:50

Live Discussion

Friday, 29 October 2021, 16:15 – 17:15

Educational Session 12: Symptomatic treatment of MS

Chair: Jalesh Panicker (London, United Kingdom)

Chair: Frank Weber (Cham, Germany)

16:15

Introduction by chairs

16:20

Neurourology

Speaker: Jalesh Panicker (London, United Kingdom)

16:35

Spasticity

Speaker: Frank Weber (Cham, Germany)

16:50

Neuropathic pain

Speaker: Xavier Moisset (Clermont-Ferrand, France)

17:05

Live Discussion

Friday, 26 November 2021, 15:00 – 16:00

Educational Session 18: Statistic evaluation of clinical and observational trials

Chair: Maria Pia Sormani (Genoa, Italy)

Chair: Florian Deisenhammer (Innsbruck, Austria)

15:00

Introduction by chairs

15:05

Interpreting Propensity Score adjusted studies

Speaker: Maria Pia Sormani (Genoa, Italy)

15:20

Methods to analyse relapses and MRI lesions

Speaker: Brian Healy (Boston, United States)

15:35

Statistical significance and clinical relevance

Speaker: Florian Deisenhammer (Innsbruck, Austria)

15:50

Live Discussion

Friday, 26 November 2021, 16:15 – 17:15

Educational Session 20: Specific aspects of MS rehabilitation

Chair: Jennifer Freeman (Plymouth, United Kingdom)

Chair: Peter Feys (Hasselt, Belgium)

16:15

Introduction by chairs

16:20

Rehabilitation in progressive MS

Speaker: Jennifer Freeman (Plymouth, United Kingdom)

16:35

Assistive technologies/devices and robotics

Speaker: Peter Feys (Hasselt, Belgium)

16:50

Managing cognitive dysfunction

Speaker: Aurélie Ruet (Bordeaux, France)

17:05

Live Discussion

Track 3 Pathology

Thursday, 14 October 2021, 12:00 – 13:00

- 12:00 – 13:00 **Educational Session 5: Pathology of MS**
Chair: Roberta Magliozzi (Verona, Italy)
Chair: Hans Lassmann (Wien, Austria)
- 12:00 **Introduction by chairs**
- 12:05 **Inflammatory reaction within the CNS of multiple sclerosis patients: mechanisms and potential triggers**
Speaker: Inge Huitinga (Amsterdam, Netherlands)
- 12:20 **Meningeal inflammation**
Speaker: Roberta Magliozzi (Verona, Italy)
- 12:35 **The pathology of multiple sclerosis and MOG antibody associated inflammatory demyelinating disease: similarities and differences**
Speaker: Hans Lassmann (Wien, Austria)
- 12:50 **Live Discussion**

Thursday, 14 October 2021, 15:00 – 16:00

- 15:00 **Educational Session 6: Infections and MS**
Chair: Thomas Berger (Vienna, Austria)
Chair: Renaud Du Pasquier (Lausanne, Switzerland)
- 15:00 **Introduction by chairs**
- 15:05 **COVID-19 pandemic: multiple sclerosis patients under disease-modifying therapies**
Speaker: Thomas Berger (Vienna, Austria)
- 15:20 **The risk of infection among patients treated with disease-modifying therapies: factors to consider**
Speaker: Anna Fogdell-Hahn (Stockholm, Sweden)
- 15:35 **Opportunistic infections under disease-modifying therapies**
Speaker: Renaud Du Pasquier (Lausanne, Switzerland)
- 15:50 **Live Discussion**

Friday, 12 November 2021, 15:00 – 16:00

- 15:00 **Educational Session 13: Targeting progression and promotion of functional tissue recovery in the CSN**
Chair: Tanja Kuhlmann (Münster, Germany)
Chair: Martin Kerschensteiner (Munich, Germany)
- 15:00 **Introduction by chairs**
- 15:05 **Reasons for impaired remyelination in multiple sclerosis: previous concepts revisited**
Speaker: Tanja Kuhlmann (Münster, Germany)
- 15:20 **Neuroplasticity: its relevance for multiple sclerosis**
Speaker: Martin Kerschensteiner (Munich, Germany)

15:35 **Lessons from recent and ongoing treatment trials in progressive MS**
Speaker: Robert J. Fox (Cleveland, United States)

15:50 **Live Discussion**

Friday, 12 November 2021, 16:15 – 17:15

Educational Session 15: Immunology of MS

Chair: Mireia Sospedra Ramos (Zurich, Switzerland)

Chair: Marco Prinz (Freiburg, Germany)

16:15 **Introduction by chairs**

16:20 **B cells and antibodies: the role of promoting inflammatory CNS demyelination**

Speaker: Markus Reindl (Innsbruck, Austria)

16:35 **T cells in multiple sclerosis: novel insights in immunopathogenesis**

Speaker: Mireia Sospedra Ramos (Zurich, Switzerland)

16:50 **Innate immune cells in MS**

Speaker: Martin Diebold (Freiburg, Germany)

17:05 **Live Discussion**

Friday, 10 December 2021, 15:00 – 16:00

Educational Session 21: Animal models of MS

Chair: Jennifer Gommerman (Toronto, United States)

Chair: Roland Liblau (Toulouse, France)

15:00 **Introduction by chairs**

15:05 **Phenotype and function of leukocytes in brain inflammation: discovery of new druggable pathways**

Speaker: Katerina Akassoglou (San Francisco, United States)

15:20 **The regulation of neuroinflammation: from animal models to humans**

Speaker: Jennifer Gommerman (Toronto, United States)

15:35 **Treatment of multiple sclerosis: what can we learn from animal models**

Speaker: Roland Liblau (Toulouse, France)

15:50 **Live Discussion**

Friday, 10 December 2021, 16:15 – 17:15

Educational Session 23: Immunological MOAs of novel MS DMTs

Chair: Eva Kubala Havrdová (Prague, Czech Republic)

Chair: Amit Bar-Or (Philadelphia, United States)

16:15

Introduction by chairs

16:20

What does not work in multiple sclerosis: lessons from failed clinical trials

Speaker: Eva Kubala Havrdová (Prague, Czech Republic)

16:35

Treatment of progressive multiple sclerosis: potential new targets

Speaker: V. Wee Yong (Calgary, Canada)

16:50

MOA of BTK inhibitors

Speaker: Amit Bar-Or (Philadelphia, United States)

17:05

Live Discussion

Track 4 MS differential diagnosis

Wednesday , 13 October 2021, 12:00 – 13:00

Educational Session 1: MOGAD: differentiating from MS and AQP4 NMOSD

Chair: Jacqueline Palace (Oxford, United Kingdom)

Chair: Brenda Banwell (Philadelphia, United States)

12:00

Introduction by chairs

12:05

Clinical features and neuroimaging in MOGAD: Differentiation from MS and NMOSD

Speaker: Jacqueline Palace (Oxford, United Kingdom)

12:20

Application and limitation of MOG antibody assays

Speaker: Fabienne Brilot (Sydney, Australia)

12:35

Treatment strategy and future outlook in MOGAD

Speaker: Brenda Banwell (Philadelphia, United States)

12:50

Live Discussion

Friday, 15 October 2021, 15:00 – 16:00

Educational Session 8: Beyond MS: Paraneoplastic syndromes, iatrogenic demyelination and autoimmune encephalitis

Chair: Josep Dalmau (Barcelona, Spain)

Chair: Reinhard Hohlfeld (Munich, Germany)

15:00

Introduction by chairs

15:05

**A practical update: Diagnosis and management of paraneoplastic and autoimmune
encephalitis**

Speaker: Josep Dalmau (Barcelona, Spain)

15:20

CNS Demyelination complicating immunotherapies: a rising spectrum

Speaker: Reinhard Hohlfeld (Munich, Germany)

15:35

**Rare but paradigmatic inflammatory CNS disorders: Rasmussen, SUSAC, CLIPPERS,
Narcolepsy**

Speaker: Alexandre Prat (Montreal, Canada)

15:50

Live Discussion

Friday, 12 November 2021, 15:00 – 16:00

Educational Session 14: Insights in neuropathology and diagnosis of NMOSD

Chair: Christine Stadelmann-Nessler (Göttingen, Germany)

Chair: Romain Marignier (Lyon, France)

15:00

Introduction by chairs

15:05

Neuropathology underlying NMOSD: Are AQP-4 antibody positive and negative cases one entity?

Speaker: Christine Stadelmann-Nessler (Göttingen, Germany)

15:20

Diagnosis of NMOSD

Speaker: Brian Weinschenker (Rochester, United States)

15:35

Clinical spectrum of NMOSD: Common and rare manifestations

Speaker: Romain Marignier (Lyon, France)

15:50

Live Discussion

Friday, 12 November 2021, 16:15 – 17:15

16:15 – 17:15

Educational Session 16: Old and new players in the treatment of NMOSD

Chair: Kazuo Fujihara (Sendai, Japan)

Chair: Tania Kümpfel (Munich, Germany)

Track 4

16:15

Introduction by chairs

16:20

Treatment targets in NMOSD: A pathophysiological view

Speaker: Kazuo Fujihara (Sendai, Japan)

16:35

Considerations for clinical trial design in rare diseases such as NMOSD

Speaker: Sean Pittock (Rochester, United States)

16:50

Current standard of care and new emerging treatments in NMOSD

Speaker: Tania Kümpfel (Munich, Germany)

17:05

Live Discussion

Friday, 10 December 2021, 15:00 – 16:00

Educational Session 22: From typical to atypical demyelination – the role of MRI in identifying MS and characterising its variants (MAGNIMS)

Chair: Christian Enzinger (Graz, Austria)

Chair: Olga Ciccarelli (London, United Kingdom)

Track 4

15:00

Introduction by chairs

15:05

Brain MRI findings suggestive of demyelination but atypical for MS

Speaker: Christian Enzinger (Graz, Austria)

- 15:30 **Spinal cord MRI findings atypical for MS**
Speaker: Olga Ciccarelli (London, United Kingdom)
- 16:00 **New MRI techniques to characterise MS variants**
Speaker: Frederik Barkhof (Amsterdam, Netherlands)
- 15:50 **Live Discussion**
Speaker: Frederik Barkhof (Amsterdam, Netherlands)

Friday, 10 December 2021, 16:15 – 17:15

Educational Session 24: Autoimmune demyelinating CNS diseases beside NMOSD and MOGAD

Chair: Samia Khoury (Beirut, Lebanon)

Chair: Yael Hacohen (London, United Kingdom)

- 16:15 **Introduction by chairs**
- 16:20 **Clinical and neuroimaging features in rare CNS demyelinating diseases and systemic autoimmune diseases with CNS involvement**
Speaker: Dean M Wingerchuk (Scottsdale, United States)
- 16:35 **How useful are biomarkers for differential diagnosis in CNS demyelination? ACE, ANA & co and their limitation**
Speaker: Samia Khoury (Beirut, Lebanon)
- 16:50 **Post-infectious and post-vaccination CNS demyelination**
Speaker: Yael Hacohen (London, United Kingdom)
- 17:05 **Live Discussion**